MA
ALXN

Montag & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Montag & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-18,054
Closed -$2.51M – 328
2018
Q3 		$2.51M Buy
18,054
+6,889
+62% +$864K 0.22% 108
2018
Q2 		$1.39M Buy
+11,165
New +$1.3M 0.14% 142

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Montag & Associates's ALXN Position: Q4 2018 in Review

Montag & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 18,054 shares — an estimated $2.51M sold.

Montag & Associates first reported a position in ALXN in Q2 2018 and held it in 2 quarters. The position peaked at $2.51M in Q3 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Montag & Associates reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Montag & Associates sold 18,054 Alexion Pharmaceuticals shares in Q4 2018, an estimated $2.51M.
  • Montag & Associates first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Montag & Associates's Alexion Pharmaceuticals position peaked at $2.51M in Q3 2018.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Montag & Associates's 13F filing for Q4 2018, filed 6 Feb 2019.